Kodein Stærk "dak" (Codeine Phosphate Hemihydrate)

Codeine phosphate is a pro‑drug that is partially converted to morphine by the liver enzyme CYP2D6. The resulting morphine binds to μ‑opioid receptors in the central nervous system, reducing the transmission of pain signals and dampening the cough reflex. This receptor activation also decreases the release of neurotransmitters such as substance P, contributing to its analgesic effect.

The exact dose of Kodein Stærk "dak" is determined by the prescribing clinician based on the individual’s pain intensity, cough severity, age, weight, renal and hepatic function, and any concomitant medications. Because dosing varies widely, the prescriber sets the appropriate regimen and provides specific instructions for each patient.

Safety data for codeine phosphate in pregnancy and lactation are limited, and the drug is generally classified as contraindicated or to be used only when the potential benefit outweighs the risk. Codeine can cross the placenta and be excreted in breast milk, potentially causing respiratory depression in the newborn. Consultation with a healthcare professional is essential before use.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with non‑opioid cough suppressants such as dextromethorphan, codeine provides stronger antitussive activity but carries opioid‑related risks like dependence and respiratory depression. In analgesia, codeine offers moderate pain relief, sitting between mild agents such as paracetamol and stronger opioids like morphine. Choice depends on the severity of symptoms and the patient’s risk profile.

Store Kodein Stærk "dak" at room temperature, below 25 °C, in the original container. Keep the product away from moisture, direct sunlight and sources of heat. Do not store in the bathroom or near a kitchen sink, and keep it out of reach of children.

Kodein Stærk "dak" is administered orally, typically as a tablet that is swallowed whole with water. The prescriber will indicate the exact dosing schedule, which may be taken with or without food depending on the patient’s tolerance. Patients should follow the label instructions and not exceed the prescribed amount.

The most serious risks include respiratory depression, especially in patients with underlying lung disease or when combined with other CNS depressants, severe allergic reactions (anaphylaxis), and the potential for dependence, addiction or withdrawal symptoms with prolonged use. Any signs of shallow breathing, rash, swelling or unusual cravings should prompt immediate medical attention.

Kodein Stærk "dak" should be avoided in individuals with known hypersensitivity to codeine or other opioids, severe respiratory insufficiency, acute or severe asthma, paralytic ileus, and in patients taking MAO inhibitors. It is also contraindicated in children under the age specified by local regulations and in anyone for whom an opioid is medically inappropriate.